October 3, 2023 : Pneumagen, a clinical-stage biotechnology company, has announced positive results from a phase 2 human challenge study of its intranasal flu antiviral, Neumifil. The study, conducted at a single center in London, UK, enrolled 104 healthy adults who received two doses of Neumifil before being intentionally exposed to the influenza virus.
The study’s primary endpoint was to assess the efficacy of Neumifil in reducing the incidence of symptomatic influenza infection. The results showed that Neumifil was highly effective in preventing symptomatic flu infection, with a 72% reduction in the incidence of symptomatic infection compared to the placebo group.
In addition, Neumifil was also shown to be effective in reducing the severity of symptoms in those participants who did become symptomatic. The mean symptom score was significantly lower in the Neumifil group than in the placebo group.
Neumifil was well-tolerated in the study, with no serious adverse events reported. The most common adverse events, such as nasal congestion and headache, were mild and transient.
These results are highly encouraging and suggest that Neumifil has the potential to be a valuable new tool for the prevention and treatment of influenza. Neumifil is an intranasal spray, which makes it easy to administer and could be particularly beneficial for at-risk populations, such as the elderly and those with underlying medical conditions.
The company plans a phase 3 clinical trial of Neumifil in at-risk populations. If successful, Neumifil could be a breakthrough in the fight against influenza.